EUS Elastography of the Pancreas: Differential Diagnosis of Chronic Pancreatitis and Solid Tumor
The differential diagnosis of focal chronic pancreatitis and solid pancreatic tumors remains one of the most challenging clinical tasks. EUS elastography is considered within the EFSUMB guidelines as one of the tools complementing endoscopic ultrasound in the evaluation of focal pancreatic lesions.
Role of EUS and EUS Elastography
According to verified responses from the Medtrain consortium (2026), endoscopic ultrasound (EUS) is considered the 'gold standard' for small lesions (<2 cm), and biopsy under EUS-FNA guidance provides morphological verification. EUS elastography serves as a method for assessing tissue stiffness, applicable for differentiating benign from malignant lesions, as well as for quantitative assessment of pancreatic fibrosis.
In the literature cited in the EFSUMB guidelines (INVUS, Part IV, Jenssen et al., 2016), EUS elastography is described as a method for differentiating benign from malignant pancreatic lesions, as well as distinguishing adenocarcinoma from inflammatory masses based on systematic reviews and meta-analyses.
Combined Techniques
According to the EFSUMB guidelines on elastography (Săftoiu et al., 2019) and CEUS in non-hepatic applications (Sidhu et al., 2018), combined approaches are used to differentiate focal chronic pancreatitis from pancreatic cancer: EUS elastography, contrast-enhanced endosonography with high mechanical index (CEHMI) and low mechanical index (CELMI), as well as the combination of contrast-enhanced power Doppler and real-time elastography.
Quantitative analysis of pancreatic fibrosis by EUS elastography has been compared with surgical samples (Itoh et al., 2014), confirming the method's applicability for assessing the degree of fibrotic changes in chronic pancreatitis.
Place in the Diagnostic Algorithm
According to Medtrain (2026), when a solid pancreatic tumor is suspected, MSCT with intravenous contrast (triple phase) is also used for staging and assessing vascular invasion, MRI with MRCP, contrast-enhanced ultrasound (CEUS) for evaluating vascularization and differential diagnosis of solid/cystic lesions. Laboratory tests determine CA 19-9 and CEA when adenocarcinoma is suspected, IgG4 when autoimmune pancreatitis is suspected.
Specific threshold values for stiffness (strain ratio, kPa) are not specified in the provided excerpts [to be clarified].
Frequently asked questions
Does EUS elastography replace biopsy for focal pancreatic lesions?
No. Verification of solid lesions is performed by biopsy under EUS-FNA guidance; elastography serves as an additional method for assessing tissue stiffness (Medtrain, 2026).
Can elastography distinguish adenocarcinoma from inflammatory masses?
In meta-analyses cited by EFSUMB (Jenssen et al., 2016), EUS elastography is described as a method for differentiating adenocarcinoma from inflammatory masses, as well as benign from malignant lesions.
What methods are combined with elastography for differential diagnosis?
Contrast-enhanced endosonography (CEHMI, CELMI) and the combination of contrast-enhanced power Doppler with real-time elastography (EFSUMB, Sidhu et al., 2018; Săftoiu et al., 2019).
Is elastography applicable for assessing fibrosis in chronic pancreatitis?
Yes, quantitative analysis of fibrosis by EUS elastography has been compared with surgical samples (Itoh et al., 2014).
What are the specific stiffness thresholds for differentiation?
Numerical thresholds are not provided in the available excerpts [to be clarified].